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Abstract. 
Chemical modifications aimed at stabilizing the interaction between the 3’-
end of siRNAs and the PAZ domain of RISC have been tested for their effect 
on RNAi activity. Such modifications contribute positively to the stability of 
siRNAs in human serum. 
 
 
RNA interference (RNAi) is a powerful gene regulatory process that 
allows the inhibition of genes in a very specific way.1 This process is 
triggered by double stranded RNAs known as small interfering RNAs 
(siRNAs)2 and is initiated with the recognition of siRNAs by the RNA-induced 
Silencing Complex (RISC), a protein complex located in the cytoplasm. 
First, RISC binds the siRNA duplex,3 then, the passenger strand is cleaved 
and released to the cytoplasm.4 On the other hand, the complementary 
strand, known as the guide strand, is used by the active complex to find the 
target sequence along the messenger RNA (mRNA) by base 
complementarity interaction. Finally, RISC induces endonucleotic cleavage 
of the target mRNA, preventing its translation into the corresponding 
protein. 
During the last few years many efforts have been focused on the use 
of this technology as targeted therapy, since it could be useful for the 
treatment of diseases where the over-expression of genes is involved, such 
as cancer or inflammation related diseases.5 In order to develop an effective 
treatment it would be desirable to achieve long lasting effects, good 
biodistribution and high tissue, organ or cell selectivity.6 In this sense, 
several groups have modified siRNAs with a broad spectrum of chemical 
modifications in order to achieve long lasting effects and to prevent the 
degradation of siRNAs by RNases.7  
In this paper we study the effect of novel modifications at the 3’-end 
of the guide strand of siRNAs with the aim of gathering structural 
information on the complex with RISC. In particular, the binding to a 
hydrophobic pocket of the PAZ domain of Argonaute protein (the key 
component of RISC) involved in the recognition of the 3’-end of the guide 
strand. 
Crystallographic data reported for a fragment of the RISC complex 
have shown the presence of aromatic residues at the PAZ binding pocket.8 
Based on these data one could expect that the presence of aromatic 
derivatives at the 3’-end of the guide strand could stabilize its interaction 
with the PAZ pocket and therefore modulate the RNAi activity. Indeed, it 
could be considered that stabilizing the complex between the guide strand 
and the RISC complex would favour the gene inhibition process. Under this 
hypothesis Ueno and co-workers have explored the effect of aromatic 
modifications at the 3’-end of the guide strand on RNAi.9 However, no 
significant differences were observed when siRNAs of the same length (21 
nucleotides) were compared. On the other hand, crystal structures of the 
PAZ domain of Argonaute in complex with DNA–RNA duplexes reveal that 
the 30-end is released from the PAZ pocket during the cleavage of the 
mRNA.10 The data suggest that this process is necessary to allow the 
protein complex to adopt the conformation required to perform RNase 
activity. Based on these results, one could expect negative effects on RNAi 
activity for stable PAZ:guide-strand complexes. In order to explore this 
hypothesis in more detail we have modified the 3’-end of the guide strand 
with aromatic derivatives of diverse size, shape and electronic properties, 
such as pyrene, anthracene, naphthalene, trifluoromethylbenzene and 
fluorobenzene. 
Moreover, the stability of the modified siRNAs in serum has been 
evaluated.  
The modified siRNAs at the 3’-end were prepared using functionalized 
Controlled Pore Glass (CPG) solid supports, which were employed in the 
automated RNA synthesis.  
Derivatives 1a–5a were prepared from L-threoninol and the 
corresponding carboxylic acids (Scheme 1). Additionally, acetic acid was 
utilized in the preparation of a non-aromatic derivative (6a), which was 
used as control of the aromatic interaction with the PAZ domain. The 
preparation of modified siRNAs started with the addition of a carboxylic acid 
to threoninol in the presence of the coupling reagents diisopropyl 
carbodiimide and N-hydroxybenzotriazole in DMF, which gave rise to the 
corresponding amide. The protection of the primary hydroxyl function with 
the dimethoxytrityl group was performed under standard conditions. Then, 
the solid supports were functionalized with threoninol derivatives. The 
addition of succinic anhydride and dimethylaminopyridine (DMAP) to the 
threoninol derivatives yielded the corresponding carboxylic acid. This group 
was activated by the addition of 2,2’-dithiobis-(5-nitropyridine), DMAP, and 
triphenylphosphine and utilized in the amide bond formation with the amino 
groups present in the CPG support.11  
The modified solid supports were then employed in the preparation of 
RNA strands using a RNA synthesizer.12 These strands were prepared to 
target the luciferase gene, which encodes for a bioluminescent protein 
commonly employed as reporter in gene inhibition assays.2 (Guide strand: 









Scheme 1 Functionalization of solid support (CPG) with threoninol 
derivatives. HOBt: hydroxybenzotriazole; DMF: dimethylformamide; 
DMTrCl: 4,4’-dimethoxytrityl chloride; DIPEA: diisopropylethylamine; Py: 
pyridine; DMAP: 4-dimethylaminopyridine; DTNP: 2,2’-dithiobis- (5-














Fig. 1 Selected gels of siRNAs modified in the guide strand (see ESI for 
Anthra, CF3 and F gels). siRNAs were incubated with serum (50%) at 37 ºC. 
The samples were extracted with hot phenol and loaded in a denaturing gel. 
 
RNA sequences were purified by HPLC and characterized by MALDI-
TOF (see ESI). The siRNAs duplexes were prepared from a passenger and 
guide strand under proper annealing conditions.2 
First, thermal stability of the modified siRNAs was compared with the 
wild-type siRNA (WT). Significant differences were not observed when the 
modification was in the guide strand (see ESI). On the other hand, when 
the modifications were located at the 3’-end of the passenger strand a small 
increase in stability was observed compared with the WT.  
Then, the stability of the modified siRNAs in serum was evaluated. 
For this purpose, siRNAs were incubated in serum (50%) at 37 ºC for 
different periods of time. The samples were extracted with hot phenol and 
loaded into a polyacrylamide gel for analysis. The WT siRNA showed a 
significant decrease in stability after 4 and 7 h and it was completely 
degraded by nucleases after 9 h in serum. The stability of modified siRNAs 
was higher than that of WT siRNA (Fig. 1). Among them, double stranded 
siRNA having aMe group at the 30-end of the guide strand displayed 
strongly enhanced stability, with significant siRNA population after 24 h in 
serum. This is a notable result for just a single modification in RNA (see ESI 
for complete gels).  
The activity of modified siRNAs was evaluated using the dual-
luciferase assay system at different concentrations and for different periods 
of time. Only when very low concentrations of siRNAs were employed could 
some differences be observed: 320 pM and 32 pM in SH-SY5Y and in HeLa 
cells respectively. At these concentrations, siRNAs with modified guide 
strand showed significant differences in activity compared to WT (Fig. 2a 
and c). The pyrene, anthracene and naphthalene derivatives showed a 
decrease in activity. Meanwhile the other derivatives (CF3, F and Me) 
showed an activity close to the siRNA without modifications (WT). The 
results herein observed are likely to be due to the interaction of the 
modified guide strand with the binding pocket at the PAZ domain, since the 
experiments with modified passenger strand showed WT activity in all cases 
(Fig. 2b and d). In addition, the decrease in RNAi activity observed cannot 
be related to the degradation of the siRNAs due to the presence of RNases, 
because modified siRNAs exhibited better stability in serum than WT. 
The results could be explained based on stabilization effects due to 
the aromatic modifications. The pyrene, anthracene and naphthalene 
derivatives could favour π-stacking interaction with the aromatic residues of 
the binding pocket, such as Phe292, Tyr309 and Tyr277. Therefore, based 
on the report by Patel where the 3’-end should be released from the PAZ 
pocket during the RNAi process,10 an increase in stabilization could cause a 
decrease in RNAi activity. 
An alternative explanation could involve destabilizing steric effects. 
The modifications employed could be too big for the pocket thus promoting 
the dissociation of the complex between the protein and the RNA strand, 
which would lead to a decrease in activity. However, the crystal structure of 
the PAZ domain of Argonaute 2 in complex with a 9-mer siRNA-like duplex 
reported by Patel and co-workers (PDB:1si3)8a reveals that these 
modifications should fit in that pocket and therefore the steric effects should 
not be critical in this case. In addition, we performed docking experiments 
using autodock-vina13 on the PAZ domain with the aromatic moieties. The 
predicted binding affinity found for the aromatic rings showed a trend that 
matches with the observed activity: -7.9, -7.7, -6.5, -6.4 and-5.8 kcal/mol 
for pyrene, anthracene, naphthalene, trifluoromethyl benzene and 
fluorobenzene, respectively. These results suggest that the pyrene 
derivative should bind tighter than the other derivatives to the PAZ domain, 





Fig. 2 RNA interference activity of modified siRNAs. (a) Activity of guide 
modified siRNAs at 320 pM in SH-SY5Y cells. (b) Activity of passenger 
modified siRNAs at 320 pM in SH-SY5Y. (c) Activity of guide modified 
siRNAs at 32 pM in HeLa cells after 24 h. (d) Activity of passenger modified 
siRNAs at 32 pM in HeLa cells after 24 h. 
 
In view of these results, we propose that the difference in activity 
observed in these examples is more likely to be due to the stabilization 
through interaction with aromatic residues of the pocket than to 
destabilization due to steric effects. 
In summary, we have studied the effect of aromatic derivatives of 
different size at the 3’-end of siRNAs on RNAi activity. It has been found 
that RNAi activity is modulated by the substituents located at the 3’-end of 
the guide strand. Thus, this report provides a complementary strategy to 
gather information on the binding pocket of the PAZ domain of RISC, which 
could be used to design more efficient siRNAs. Moreover, we have studied 
the effect of these modifications on the serum stability of the corresponding 
modified siRNAs. We have found that a single modification at the 3’-end of 
the guide strand can significantly stabilize the corresponding siRNA in 
serum. Among the modifications tested, the methyl modification causes a 
significant increase in serum stability. Moreover, this modification does not 
adversely affect gene silencing activity, which makes it an ideal modification 
for applications in targeted therapy by RNA interference. 
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General experimental methods: Reagents were purchased from Aldrich and 
used without further purification. Thin layer chromatography was carried out 
using Silica Gel 60 F254 plates. Column chromatography was performed using 
Silica Gel (60 Å, 230 x 400 mesh). All NMR spectra were recorded on Varian 
Mercury 400 MHz (Unitat d'RMN, Serveis Cientificotècnics, Parc Cientific de 
Barcelona) instrument as solutions in the deuterated solvent indicated, and the 
chemical shifts are reported in parts per million (ppm). Coupling constants are 
reported in hertz (Hz). HRMS were performed on a LC/MSD-TOF (Agilent 
technologies) high resolution mass spectrometer by Servei d’Espectrometria de 
Masses (Universitat de Barcelona). 
 
Procedure A: Amide Formation : 
To a solution of the corresponding acid (1.2 equiv) in DMF (0.5 M) at room 
temperature, N-hydroxybenzotriazole (1.1 equiv) and diisopropylcarbodiimide 
(1.1 equiv) were added. After stirring the mixture for 5 minutes D- or L- 
Threoninol (1 equiv) was added. The resulting mixture was stirred at room 
temperature for 24 h and then quenched by the addition of methanol. The 
solvent was evaporated under vacuum and the residue purified by flash 
chromatography. 
 
Procedure B: DMTr Protection: 
To a solution of the corresponding diol (1 equiv) in pyridine (0.2 M) at 0º C, 
diidopropylethylamine (1.5 equiv), 4,4´-dimethoxyltritylchloride (1.2 equiv) and 
dimethylaminopyridine (catalytic amount) were added. After 15 min the mixture 
was allowed to reach room temperature, then it was stirred for 24 h and finally 
the reaction was quenched with methanol. The solvent was evaporated under 
vacuum and the residue purified by flash chromatography. 
 
Procedure C: CPG Functionalization (Two Steps) ( Gupta, K. C.; Kumar, P.; 
Bhatia, D.; Sharma, A. K. Nucleosides and Nucleotides, 1995, 14, 829-832):  
 
I To a solution of the corresponding alcohol (1 equiv) in dichloromethane (0.2 
M) succinic anhydride (1.3 equiv), diisopropylethylamine (1.4 equiv) and 
dimethyaminopyridine (catalytic amout) were added. The solution was stirred for 
24 h at room temperature. Then, the solution was washed with a solution of 
sodium dihydrogen phosphate (1%). The organic layer was dried over 
Magnesium sulfate, filtered and evaporated to yield a yellowish oil. 
 
II To a solution of DMAP (1.5 equiv) in acetonitrile (60 mM) the product obtained 
in step II was added (1 equiv). After mixing it well (vortex), the solution was 
added to a solution of 2,2´-dithiobis-(5-nitropyridine) (1.5 equiv). The solution 
was mixed well and added to triphenyl phosphine (1.5 equiv). The mixture was 
vortexed till all reagents were dissolved giving rise to a reddish solution, which 
was added to 200 mg of CPG (500 Ǻ). After 1 h at room temperature the 
solution was removed and the CPG washed with methanol (3 X 20 mL) and, dry 
acetonitrile (3 x 20 mL). Once the CPG was dry, 2 mL of a 1:1 mixture of the 
capping reagents utilized on oligonucleotide synthesis (Cap Mix A: Acetic 
anhydride/Py/THF; Cap Mix B: 1-Methylimidazole /THF; from GlenResearch) 
was added. After 15 min at room temperature, the CPG was washed with dry 
acetontrile (6 x 20 mL) and dried. The CPG loading was calculated by 
detrytylation of a sample as follows: 10 mg of CPG were treated with 5 mL of a 
detrytilation solution (3mL of perchloric acid and 2 mL of ethanol) for 30 min. 
Then 200 µL of the mixture were dissolved in 800 µL of the detrytilation solution 
and absorbance was measured at 498. Functionalization (F) was determined by 
Lambert-Beer law. F = (ABS x V) / (ε x gr) = M/ gr.  
 
CHARACTERIZATION OF ORGANIC COMPOUNDS 
 
N-[(2S, 3R)-1,3-dihydroxybutan-2-yl]pyrene-1-carboxamide (1a) . 
 
 
Compound 1a was obtained following procedure A. After flash chromatography 
(cyclohexane 4 / CH2Cl2 4 / MeOH 0.5) 302 mg (0.906 mMol) were obtained as 
a white solid (79%). 1H NMR (400 MHz, CD3OD): 8.53 (d, J = 9.3 Hz, 1H), 8.25 
(t, J = 7.5 Hz, 3H), 8.21-8.02 (m, 5H), 4.28 (dt, J = 6.2 and 3.6 Hz, 1H), 4.18 
(dq, J = 6.4 and 3.6 Hz, 1H), 3.87 (System ABX, JAB= 11.1 Hz, JAX = 5.8 Hz, and 
JBx= 6.6 Hz, 2H), 1.38 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CD3OD): 173.4, 
133.9, 132.8, 132.6, 132.1, 129.7, 129.6, 129.5, 128.3, 127.6, 126.9, 126.8, 
126.1, 125.8, 125.61, 125.59, 125.51, 67.5, 63.0, 58.5, 20.8. HRMS m/z: Calc 







Compound 1b was obtained following procedure B. After flash chromatography 
(cyclohexane 2 / EtOAc 1) 133 mg (0.209 mMol) were obtained as a white solid 
and 24 mg of the starting material were recovered. (70% yield, or 92% yield 
based on the recovered starting material). 1H NMR (400 Mz, CDCl3): 8.62 (d, J 
= 9.3 Hz, 1H), 8.21 (d, J = 7.7 Hz, 2H), 8.12 (s, 3H), 8.09 (d, J = 2.1 Hz, 1H), 
8.04 (t, J = 7.7 Hz, 2H), 7.45 (d, J = 7.6 Hz, 2H), 7.34 (d, J = 8.7 Hz, 4H), 7.28 
(t, J = 7.7 Hz, 2H), 7.20 (t, J = 7.2 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 6.81 (dd, J 
= 8.9 and 2.8 Hz, 4H), 4.38-4.32 (m, 1H), 4.28-4.22 (m, 1H), 3.73 (s, 3H), 3.72 
(s, 3H), 3.63 (ABX System, JAB = 9.6 Hz, JAX = 3.7 Hz, JBX = 3.6 Hz, 2H), 1.35 
(d, J = 6.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): 170.2, 158.6, 158.5, 144.3, 
135.4, 135.2, 132.6, 131.1, 130.7, 130.6, 129.9 (4C), 128.7, 128.6, 128.5, 128.0 
(2C), 127.9 (2C), 127.0, 126.9, 126.3, 125.8, 125.7, 124.7, 124.5, 124.5, 124.3, 
124.2, 113.3 (4C), 86.9, 69.0, 65.6, 55.1 (2C), 54.3, 20.3. HRMS m/z: Calc for 
C42H37NO5Na (M + Na+) 658.2563, found 658.2563. 
 




Compound 2a was obtained following procedure A. After flash chromatography 
(cyclohexane 6 / CH2Cl2 3 / MeOH 0.5) 273 mg (1.052 mMol) were obtained as 
a yellowish solid (49%). 1H NMR (400 MHz, CD3OD): 8.56 (s, 1H), 8.27-8.15 
(m, 2H), 8.06 (d, J = 8.3 Hz, 2H), 7.57-7.47 (m, 4H), 4.40 (ddd, J = 6.7, 5.6 and 
3.9 Hz, 1H), 4.15 (dq, J = 6.4 and 3.8 Hz, 1H), 3.87 (ABX System: JAB = 11.0 
Hz, JAX = 5.6 Hz, JBX = 6.9 Hz, 2H), 3.35 (s, 1H), 1.39 (d, J = 6.4 Hz, 3H). 13C 
NMR (100 MHz, D3OD): 172.7, 133.5, 132.7, 129.6 (2C), 129.3, 129.2 (2C), 
127.7 (2C), 126.6 (4C), 126.4, 67.4, 63.0, 58.8, 20.9. HRMS m/z: Calc for 







Compound 2b was obtained following procedure B. After flash chromatography 
(cyclohexane 3 / EtOAc 1) 130 mg (0.213 mMol) were obtained as a white solid 
(62%). 1H NMR (400 Mz, CDCl3): 8.48 (s, 1H), 8.11 (bs, 1H), 8.01 (d, J = 9.2 
Hz, 2H), 7.47 (t, J = 8.2 Hz, 2H), 7.41 (d, J = 7.2 Hz, 2H), 7.31 (d, J = 8.8 Hz, 
4H), 7.26 (t, J = 7.4 Hz, 2H), 7.21 (d, J= 7.0 Hz, 1H), 6.80 (d, J = 8.8 Hz, 4H), 
6.73 (d, J = 8.8 Hz, 1H), 4.49 (td, J = 7.3 and 3.9 Hz, 1H), 4.16 (m, 1H), 3.77 (s, 
3H), 3.76 (s, 3H), 3.62 (ABX System, JAB = 9.6 Hz, JAX = 3.6 Hz, JBX = 4.4 
Hz, 2H), 3.07 (s, 1H), 1.35 (d, J = 6.3 Hz, 3H). 13C NMR (100 MHz, CDCl3): 
169.9, 158.6 (2C), 144.2 (2C), 135.4, 135.1, 131.7, 131.1 (2C), 130.0 (3C), 
129.9 (3C), 128.5 (2C), 128.3, 128.1, 128.0 (2C), 127.9 (2C), 127.0, 126.7 (2C), 
125.4, 125.2, 113.3 (2C), 113.2 (2C), 86.9, 68.8, 65.5, 55.2 (2C), 54.6, 20.6. 
HRMS m/z: Calc for C40H37NNaO5 (M + Na)+ 634.2564, found 634.2570. 
 




Compound 3a was obtained following procedure A. After flash chromatography 
(cyclohexane 6 / CH2Cl2 3 / MeOH 0.5) 273 mg (1.052 mMol) were obtained as 
a yellowish solid (92%). 1H NMR (400 MHz, CD3OD): 8.26 (d, J = 9.1 Hz, 1H), 
7.95 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 7.3 Hz, 1H), 7.69 (d, J = 7.0 Hz, 1H), 7.57-
7.47 (m, 3H), 4.21-4.16 (m, 1H), 4.15-4.09 (m, 1H), 3.79 (System ABX; JAB = 
11.1 Hz, JAX = 5.8 Hz, JBX = 6.5 Hz, 2H), 1.30 (d, J = 6.4 Hz, 3H). 13C  NMR (100 
MHz, CD3OD): 173.1, 136.1, 135.3, 131.7, 131.6, 129.6, 128.2, 127.6, 126.6, 
126.5, 126.1, 67.6, 63.1, 58.4, 20.9. HRMS m/z: Calc for C15H18NO3 (M + H+) 
260.1281, found 260.1291. 
 
N-[(2S, 3R)-1-(bis(4-methoxyphenyl)(phenyl)methoxy)-3-hydroxy butan-2-




Compound 3b was obtained following procedure B. After flash chromatography 
(cyclohexane 3 / EtOAc 1) 146 mg (0.259 mMol) were obtained as a white solid 
(31%). 1H NMR (400 Mz, CDCl3): 8.37-8.32 (m, 1H), 7.95 (d, J = 8.2 Hz, 1H), 
7.92- 7.87 (m, 1H), 7.66 (dd, J = 7.0 and 1.1 Hz, 1H), 7.56-7.52 (m, 2H), 7.48 
(dd, J = 8.2 and 7.1 Hz, 1H), 7.40 (d, J = 7.2 Hz, 2H), 7.31 (d, J = 8.9 Hz, 4H), 
7.26 (t, J = 7.3 Hz, 2H), 7.20 (t, J = 7.1 Hz, 1H), 6.80 (dd, J = 8.8 and 3.7 Hz, 
4H), 6.71 (d, J = 8.8 Hz, 1H), 4.28-4.24 (m, 1H), 4.23-4.18 (m, 1H), 3.76 (s, 3H), 
3.75 (s, 3H), 3.56 (System ABX, JAB = 9.7 Hz, JAX = 3.8 Hz, JBX = 3.6 Hz, 2H), 
3.17 (s, 1H), 1.29 (d, J = 6.34 Hz, 3H). 13C NMR (100 MHz, CDCl3): 169.8, 
158.7, 158.6, 144.2, 135.4, 135.2, 134.4, 133.7, 130.7, 130.1, 129.9 (4C), 
128.3, 128.0 (2C), 127.9 (2C), 127.2, 127.0, 126.4, 125.5, 124. 9, 124.7, 113,3 
(4C), 86.9, 69.1, 65.7, 55.2 (2C), 53.9, 20.2. HRMS m/z: Calc for C36H35NNaO5 
(M + Na)+ 584.2407, found 584.2402. 
 




Compound 4a was obtained following procedure A. After flash chromatography 
(cyclohexane 4 / CH2Cl2 4/ MeOH 0.5) 157 mg (0.566mMol) were obtained as a 
white solid (60%). 1H NMR (400 MHz, CD3OD): 8.03 (d, J = 8.2 Hz, 2H), 7.78 
(d, J = 8.2 Hz, 2H), 4.14-4.04 (m, 2H), 3.75 (System ABX: JAB = 11.2 Hz, JAX = 
5.6 Hz, JBX = 6.2 Hz, 2H), 1.22 (d, J = 6.2 Hz, 3H). 13C NMR (100 MHz, 
CD3OD): 169.4, 139.7, 134.1 (q, JF-C = 32.4 Hz, 1C), 129.3 (2C), 126.5 (q, JF-C = 
3.8 Hz, 2C), 124.0, 67.3, 62.8, 58.4, 20.6. 19F NMR (376 MHz, CD3OD): -64.86. 
HRMS m/z: Calc for C12H15NO5F3 (M + H+) 278.0998, found 278.0999. 
 
N-[(2S, 3R)-1-(bis(4-methoxyphenyl)(phenyl)methoxy)-3-hydroxy butan-2-




Compound 4b was obtained following procedure B. After flash chromatography 
(cyclohexane 3 / EtOAc 1) 580 mg (0.828 mMol) were obtained as a white solid 
(77%). 1H NMR (400 Mz, CDCl3): 7.89 (d, J = 8.1 Hz, 2H), 7.73 (d, J = 8.2 Hz, 
2H), 7.38 (d, J = 7.2 Hz, 2H), 7.30-7.18 (m, 4H), 6.79 (dd, J = 8.8 and 6.8 Hz, 
2H), 4.28- 4.20 (m, 1H), 4.15-4.10 (m, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.49 
(System ABX: JAB = 9.8 Hz, JAX = 4.2 Hz, JBX = 3.4 Hz, 2H), 3.07 (s, 1H), 1.21 
(d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3): 166.3, 158.6 (2C), 144.2, 
137.6, 135.3, 135.2, 133.3 (q, JFC = 32.8 Hz, 1C), 129.9 (2C), 129.8 (2C), 128.0 
(2C), 127.8 (2C), 127.4 (2C), 127.0, 125.7 (q, JF-C = 3.8 Hz, 2C), 124.9, 113.3 
(2C), 113.2 (2C), 86.9, 68.5, 65.2, 55.1(2C), 54.0, 20.1. 19F NMR (376 MHz, 
CDCl3): -63.36. HRMS m/z: Calc for C33H32F3NNaO5 (M + Na)+ 602.2125, found 
602.2126. 
 




Compound 5a was obtained following procedure A. After flash chromatography 
(cyclohexane 5 / CH2Cl2 4 / MeOH 0.5) 180 mg (0.792 mMol) were obtained as 
a white solid (69%). 1H NMR (400 MHz, CD3OD): 7.92 (dd, J = 8.8 and 5.4 Hz, 
2H), 7.20 (t, J = 8.7 Hz, 2H), 4.13-4.02 (m, 2H), 3.73 (System ABX, JAB = 11.2 
Hz, JAX = 5.9 Hz, JBX = 6.3 Hz, 2H), 1.21 (d, J = 6.4 Hz, 3H). 13C NMR (100 
MHz, CD3OD): 169.5, 166.2 (d, JF-C = 250.5 Hz, 1C) , 132.1, 131.0 (d, JF-C = 8.9 
Hz, 2C), 116.4 (d, JF-C = 22.1Hz, 2C), 67.3, 62.8, 58.2, 20.6. 19F NMR (376 








Compound 5b was obtained following procedure B. After flash chromatography 
(cyclohexane 3 / EtOAc 1) 313 mg (0.591 mMol) were obtained as a white solid 
(45%). 1H NMR (400 Mz, CDCl3): 7.81 (dd, J = 8.8 and 5.3 Hz, 2H), 7.37 (d, J = 
7.1 Hz, 2H), 7.30-7.18 (m, 7H), 7.14 (t, J = 8.6 Hz, 2H), 6.79 (dd, J = 8.9 and 
6.8 Hz, 4H), 4.21 (d, J = 6.3 Hz, 1H), 4.15-4.05 (m, 1H), 3.77 (s, 3H), 3.76 (s, 
3H), 3.56 (dd, J = 9.7 and 4.2 Hz, 1H), 3.38 (dd, J = 9.7 and 3.4 Hz, 1H), 3.13 
(s, 1H), 1.20 (d, J = 6.37 Hz, 3H). 13C NMR (100 MHz, CDCl3): 166.6, 164 (d, 
JF-C = 252 Hz, 1C), 158.6 (2C), 144.2, 135.4, 135.2, 130.5 (d, JF-C = 3.2 Hz, 1C), 
129.9 (2C), 129.8 (2C), 129.3 (d, JF-C = 8.9 Hz, 2C), 128.0 (2C), 127.8 (2C), 
127.0, 115.6 (d, JF-C = 21.8 Hz, 2C), 113.3 (4C), 86.9, 68.9, 65.5, 55.2 (2C), 
53.9, 20.0. 19F NMR (376 MHz, CDCl3): -108.44. HRMS m/z: Calc for 
C32H32NO5FNa (M + Na+) 552.2156, found 552.2143. 
 




Compound 6a was obtained following procedure A. After flash chromatography 
(cyclohexane 4 / CH2Cl2 4 / MeOH 0.5) 159 mg (1.08 mMol) were obtained as a 
colorless oil (76%). 1H NMR (400 MHz, CD3OD): 4.04-3.94 (m, 1H), 3.84-3.76 
(m, 1H), 3.61 (System ABX, JAB = 11.0 Hz, JAX = 5.9 Hz, JBX = 6.3 Hz, 2H), 2.00 
(s, 3H), 1.14 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CD3OD): 173.8, 67.2, 








Compound 6b was obtained following procedure B. After flash chromatography 
(cyclohexane 1 / EtOAc 3) 85 mg (0.189 mMol) were obtained as a yellowish 
solid. 1H NMR (400 Mz, CDCl3): 7.38 (d, J = 7.3 Hz, 2H), 7.27 (d, J = 8.8 Hz, 
6H), 7.22 (t, J = 7.2 Hz, 1H), 6.83 (d, J = 8.74 Hz, 4H), 6.05 (d, J = 8.7 Hz, 1H), 
4.15-4.06 (m, 1H), 3.94-3.88 (m, 1H), 3.79 (s, 6H), 3.35 (System ABX, JAB = 9.7 
Hz, JAX = 4.4 Hz, JBX = 3.5 Hz, 2H), 3.02 (s, 1H), 2.02 (s, 3H), 1.13 (d, J = 6.4 
Hz, 3H). 13C NMR (100 MHz, CDCl3): 170.4, 158.7 (2C), 144.3, 135.5, 135.3, 
129.9 (2C), 129.8 (2C), 128.0 (2C), 127.9 (2C), 127.0, 113.3 (4C), 86.9, 68.7, 
65.4, 55.2 (2C), 53.4, 23.3, 19.9. HRMS m/z: Calc for C27H31NNaO5 (M + Na)+ 
472.2100, found: 472.2096. 
 
RNA synthesis and purification methods: 
RNA oligonucleotides were synthesized in a ABI 394 DNA / RNA Synthesizer 
using 2’-TBDMS phosphoramidites (Sigma-Aldrich). RNA oligonucleotides were 
synthesized on the 1 µmol scale. After solid-phase synthesis, the solid support 
was transferred to a screw-cap glass vial and incubated at 55 ºC for 1 h with 1.5 
mL of NH3 solution (33%) and 0.5 mL of ethanol. After the vial was cooled 
briefly on ice, the supernatant was transferred by pipet into 2 mL Eppendorf 
tubes; the solid support and vial were rinsed with 50% ethanol (2 × 0.25 mL). 
The combined solutions were evaporated to dryness using an evaporating 
centrifuge. The residue was dissolved in a total volume of 0.33 mL of TBAF 
(1M) in THF and rocked at room temperature for 12 h. Then, 0.33 mL of 
Et3NHAcO (1 M) and 0.33 mL of water were added to the solution, and the 
oligonucleotide was desalted on a NAP-10 column using water as the eluent 
and evaporated to dryness. The oligonucleotides were purified by HPLC (DMT-
ON). The pure fractions were combined and evaporated to dryness. The 
residues were treated with 0.4 mL of AcOH solution (3%) and incubated at room 
temperature for 1 h. The deprotected oligonucleotides were purified by HPLC 
(DMT-OFF). The pure fractions were combined and evaporated to reach a 




All synthesized oligonucleotides were characterized by MALDI-TOF mass 
spectrometry: 
 




WT GS UCGAAGUAUUCCGCGUACGTT 6646.2 6646.2 
Py GS UCGAAGUAUUCCGCGUACGT-Py 6736.1 6731.1 
Anthra GS UCGAAGUAUUCCGCGUACGT-Anthra  6712.1 6707.8 
Naph GS UCGAAGUAUUCCGCGUACGT-Naph  6662.1 6657.4 
CF3 GS UCGAAGUAUUCCGCGUACGT-CF3 6680.1 6673.3 
F GS UCGAAGUAUUCCGCGUACGT-F 6630.1 6625.6 
Me GS UCGAAGUAUUCCGCGUACGT-Me 6550.1 6550.9 
WT PS CGUACGCGGAAUACUUCGATT 6669.2 6669.4 
Py PS CGUACGCGGAAUACUUCGAT-Py 6759.1 6753.5 
Anthra PS CGUACGCGGAAUACUUCGAT-Anthra  6735.1  6735.3 
Naph PS CGUACGCGGAAUACUUCGAT-Naph  6685.1 6686.4 
CF3 PS CGUACGCGGAAUACUUCGAT-CF3 6703.1 6707.4 
F PS CGUACGCGGAAUACUUCGAT-F 6653.1 6656.6 
Me PS CGUACGCGGAAUACUUCGAT-Me 6573.1 6576.9 
 
GS: Guide Strand; PS: Passenger Strand. 
 
Thermal Stability of siRNAs 
For annealing of siRNAs, a solution of guide and passenger strand at 
20µM in annealing buffer (100mM potassium acetate, 30mM HEPES-KOH at 
pH 7.4, 2mM magnesium acetate) were incubated for 1 min at 92 ºC and cooled 
down slowly to room temperature.  
SiRNAs (0.5 µM each) were dissolved in buffer (50 mM potassium 
acetate, 1 mM magnesium acetate, 15 mM HEPES-KOH at pH 7.4). 
Experiments were performed in Teflon-stoppered 1 cm path length quartz cells 
on a JASCO V-650 spectrophotometer equipped with thermoprogrammer. The 
denaturation experiments were done at a rate of 1 °C/min to 90 °C, monitoring 
absorbance at 260 nm. In all cases the complexes displayed sharp, apparently 
two-state transitions. The data were analyzed by the denaturation curve 
processing program, MeltWin v. 3.0. Melting temperatures (Tm) were 




Stability of siRNAs in 50% human serum 
Unmodified or modified double-stranded siRNA samples (20 µM; 24 µL) were 
incubated in human serum (24 µL) at 37 ºC. At appropiate periods (0, 0.5, 1, 2, 
4, 7 and 9 hours), 6 µL aliquots of the reaction mixture were added to 54 µL of a 
1% sodium dodecyl sulphate aqueous solution and the mixtures were heated-
denatured for 5 min at 90 ºC. siRNAs were isolated by hot phenol extraction 
followed by ethanol precipitation. In the case of F and CF3 the hot phenol 
extraction was skipped due to problems with the extraction. After re-suspension 
in 20 µL of loading buffer (90% formamide, 10% 1X TBE), the samples were run 
on a denaturing 14% polyacrylamide gel containing 20% formamide. RNA 
bands were visualized with the SYBR Green II reagent (Sigma-Aldrich) 











RNA interference methods 
SH-SY5Y and Hela cells were grown at 37 ºC, 5% CO2 in Dulbecco’s modified 
Eagles’s medium (DMEM, GIBCO) supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. The cells were 
maintained in exponential growth. The cells were plated in 24-well plates (0.5 
mL medium/well) to reach about 50% confluence at transfection. The cells were 
grown for 24 h and the culture medium was changed to OPTIMEM 1 (GIBCO), 
0.5 mL/well. Two luciferase plasmids, firefly luciferase (pGL2) and Renilla 
luciferase (pRL-CMV) from Promega, were used as reporter and control, 
respectively. Co-transfection of plasmids and siRNAs was carried out with 
Lipofectamine 2000 (Invitrogen) as described by the manufacturer for adherent 
cell lines. Per well, 1.0 µg pGL2, 0.1 µg pRL-CMV and the required amount of 
siRNAs, formulated into liposomes, were applied. The final volume was 500 µL 
per well. The cells were harvested 24 h after transfection, and lysed by using 
passive lysis buffer (PLB), 100 µL per well, according to the instructions of the 
Dual-Luciferase Reporter Assay System (Promega, USA). The luciferase 
activities of the samples were measured using a MicroLumaPlus LB 96V 
(Berthold Technologies) with a delay time of 2 s and an integrate time of 10 s. 
The volumes used were: 20 µL of sample and 30 µL of each reagent (luciferase 
assay reagent II and Stop & Glo Reagent). The inhibitory effects generated by 
siRNAs were expressed as normalized ratios between the activities of the 
reporter GL2 (Photinus pylaris) luciferase gene and the control RL (Renilla 
reniformis) luciferase gene. 
 
Autodock-vina docking. (O. Trott, A. J. Olson J. Comput. Chem. 2009, DOI: 
10.1002/jcc.21334).  
 
The protein (PDB: 1si3) and the ligands (pyrene, anthracene, naphthalene, 
trifluoromethyl benzene and fluorobenzene) were prepared for the docking 
using 
autodock tools (ADT) (M. F. Sanner. J. Mol Graphics Mod. 1999, 17, 57-61).  The 
following parameters were employed in the docking: 
 
Search Space: 
Center:_x = 16.837. 
Center_y = 77.117. 
Center_z: –13.227. 
Size_x: 12 angstroms. 
Size_y: 12 angstroms. 
Size_z: 12 angstroms. 
Exhaustiveness: 300. 
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